<qa>  What is the name of the VERSUS ORAL ADJUSTED-DOSE WAEVALUATION OF WEEKLY IDRABIOTAPARINUX SODIUM VERSUS ORAL ADJUSTED-DOSE WARFARIN TO PREVENT STROKE AND SYSTEMIC THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION: 